Interaction screening. Reconstitution math. Longitudinal monitoring.
Every compound we run mapped to the tissue it acts on, the marker it moves, the system it pivots. Touch a region, see the protocol behind it.
Six sequential gates. Each produces a verifiable artifact. Nothing ships until all six open.
Every compound is assigned a tier. Quality floor: analytical testing, traceability. Non-negotiable.
| Capability | Typical Prescription | The Pivotal Protocol |
|---|---|---|
| Interaction screening | Manual, reactive | Automated at design |
| Reconstitution math | Left to end-user | Pre-computed per vial |
| Dose ramping plan | Not specified | Encoded with hold gates |
| Lab monitoring cadence | Ad hoc | Baseline, midpoint, endpoint |
| Washout scheduling | Rarely documented | Built into the cycle |
| Label traceability | Generic | Protocol-bound, lot-traced |
| Anonymized client document | None | Auto-generated per cycle |
| Adjustment protocol | New visit | Response-vector-driven |
Design surface. Not a storefront.
Compound, mass, BAC volume, dose, cost in. Concentration, draw volume, U-100 units, cost per dose out.
Each compound maps to a defined instrument panel. You do not fly without instruments.
Tirzepatide, Semaglutide, Retatrutide. Monitored against fasting glucose, HbA1c trajectory, weight and waist vectors, lipid shifts, and side-effect load. Ramp cadence protects tolerability.
BPC-157, TB-500, KPV, GHK-Cu. Monitored against ROM, pain scale, inflammatory markers, and target-tissue imaging where indicated. Paired with load progression protocols.
MOTS-c, SS-31. Monitored against resting heart rate variability, VO2 or work-capacity proxies, recovery scores, and energy metabolism panels. Cycled, not chronic.
Tesamorelin, CJC-1295, Ipamorelin. Monitored against IGF-1, visceral adiposity, sleep architecture, and recovery markers. Evening-weighted dosing to preserve pulsatility.
Pooled across active cohorts. Ranges, not averages. Anonymized.
Three de-identified clients. Actual biomarker trajectories, intake to endpoint.
Anonymized. Ranges reported. Individual response varies. These are observations, not outcomes guarantees.
Ten biomarkers. One anonymized operator log. 18 months apart.
Single anonymized operator. Clinically verified longitudinal record. Observational data only. Individual results depend on baseline, protocol adherence, and co-interventions.
Single peptide chain. Lowest-energy conformation. Precision biology, not a wellness choice.
“The most dangerous thing in this field is confidence without arithmetic. Every dose is a calculation. Every stack is an interaction. Every cycle is a measurement. A protocol is what separates a compound from a practice.”
White-label protocol documents, interaction screening, and client monitoring cadence under your licensed care model. Every document is built for co-signature. Referral pathway included. Zero liability language on every output.
Recovery, tissue repair, and growth-axis cycles engineered around training load and periodization. Protocols phased to peak, deload, and off-season blocks. HRV, output markers, and lab panels monitored at every cycle stage.
Multi-axis protocols for long-horizon optimization. Metabolic, mitochondrial, and growth axes coordinated against quarterly labs and recovery telemetry. Cycles are designed with an exit. Every protocol has a washout plan and a next-cycle logic.
Each capability below is a structural output of the Keel intelligence framework. Not a policy. An architecture.
No other peptide service runs a systematic interaction gate before protocol output. We do it on every design, every revision, every cycle change. Conflict flags are documented in the protocol file, not noted verbally.
Concentration, volume, units per draw, doses per vial, BAC-to-peptide backfill ratio. Every client receives a reconstitution document that shows the full calculation, not just the dose. Errors at reconstitution are protocol errors. We treat them that way.
Midpoint check. Endpoint labs. Outcome scored against intake goals. Every protocol closes with a documented result. If the result did not match the intent, the next design starts from that truth, not from a reset.
The Pivotal research vault holds tiered citations behind every compound in the library. Tier A is peer-reviewed human data. Tier B is animal or in-vitro with human plausibility. Tier C is flagged as exploratory. No compound recommendation ships without a citation tag.
Every client receives a formatted protocol document: compound list, dosing table, reconstitution instructions, monitoring schedule, interaction notes, and washout plan. Version-locked. Signed. Delivered over zero-trust access. Not a PDF attachment in an email.
The Pivotal Protocol references a quality tier for every compound in every protocol. Third-party analytical testing and label traceability. We do not design around compounds that cannot meet the assigned floor. That is a structural constraint, not a preference.
Two dominant models. Neither is what we are.
A human reads every submission and responds directly. No CRM. No funnel.
We flag mismatches immediately. We tell you what we can do and what we cannot. That is the first reply.
One intake form. One human reviewer. Inside one business day, you know whether this is the right route for you. No automation. No upsell. Just a straight answer from someone who has read every word you wrote.
